Qizheng Tibetan Medicine has been honored with two awards: “Pioneer of High-Quality Development” and “Best Board of Directors for Investor Relations.”

　　On April 26, the "2019 First China Listed Companies High-Quality Development Forum," hosted by Securities Times, was held in Beijing. During the forum, a list of the Top 100 High-Quality Companies was released. Qizheng Tibetan Medicine won two prestigious awards: "Pioneer of High-Quality Development for Chinese Listed Companies" and "Best Board of Directors for Investor Relations." The company earned recognition from the capital market thanks to its focus on its core business, steady growth, standardized operations, and a board of directors that is open-minded, pragmatic, and highly effective in governance. The event was attended by executives from 300 leading listed companies, as well as prominent economists, seasoned sell-side analysts, and elite professionals from the investment community.

　　In 2018, the Securities Times launched a large-scale series of reports titled “High-Quality Development in Action by Listed Companies,” aimed at promoting the spirit of reform and opening-up, driving China’s economic transformation and upgrading, harnessing positive energy from the capital market, and exploring and publicizing the successful experiences of China’s outstanding listed companies in achieving high-quality development. Over nearly a year, the initiative visited 100 high-quality listed companies across various sub-sectors—companies characterized by large market capitalization, strong profitability, remarkable growth potential, generous cash dividends, and robust technological competitiveness. This series of reports attracted widespread attention from all sectors of society, achieved excellent dissemination results, and was awarded the First Prize in the “China Capital Market News Reporting Excellence Awards (2018)” presented by the China Securities Regulatory Commission, as well as the First Prize for Outstanding Works in 2018 from the People’s Daily’s affiliated newspapers and periodicals.

　　Last year, the “High-Quality Development in Action” reporting team from the Securities Times visited Qizheng Tibetan Medicine and engaged in an in-depth conversation with Ms. Lei Jufang, the company’s chairwoman, covering topics such as the company’s development journey, brand characteristics, strategic planning, and sustainable development.

　　In 2009, Qizheng Tibetan Medicine was listed on the SME Board of the Shenzhen Stock Exchange and has become the largest Tibetan medicine manufacturer in China. Over more than two decades of development, the company has adhered to the concept of sustainable development, dedicating itself to gaining deep insights into patient needs, pursuing innovation and upgrading within the industry, focusing on the growth and development of its employees, safeguarding and passing on Tibetan medical culture, and promoting the protective and responsible utilization of resources on the Qinghai-Tibet Plateau. By fostering close collaboration and shared values with its partners, the company strives to co-create sustainable, shared value together with various stakeholders—including investors—and thereby drive its own enduring success and long-term sustainability.

　　Qizheng Tibetan Medicine believes that, as a publicly listed company, the company’s own high-quality development is the best protection for investors. Since its listing, the company has focused on operating in compliance with laws and regulations, staying true to its core business, and maintaining stable, sustainable growth. It is committed to creating value for the company, enabling investors to fully share in the benefits of the company’s growth and grow together with the company. Consistent long-term performance and a high rate of investor returns have become two prominent hallmarks of Qizheng Tibetan Medicine in the A-share market. Since its IPO in 2009, the company has achieved net profits totaling 354 million yuan, representing a year-on-year increase of 9.98%; net profits attributable to shareholders of the listed company reached 319 million yuan, up 5.96% from the previous year; cash dividends distributed amounted to 166 million yuan, with cumulative cash dividends totaling 1.436 billion yuan. The company has paid a total of 215 million yuan in taxes, including 188 million yuan paid in Tibet, bringing its cumulative tax payments over the years to 2.014 billion yuan. For several consecutive years, the company has been recognized as an outstanding taxpayer in both the Tibet Autonomous Region and the Linzhi region.